BSD Medical Corporation Announces Investor and Analyst Conference Call

  BSD Medical Corporation Announces Investor and Analyst Conference Call

Live Conference Call and Webcast Scheduled for Thursday, July 11 at 2:00 p.m.
             Eastern Time/12:00 p.m. Mountain Time; RSVP Required

Business Wire

SALT LAKE CITY -- June 25, 2013

BSD Medical Corporation (NASDAQ: BSDM) (“Company” or “BSD”), a leading
provider of medical systems that utilize heat therapy to treat cancer, today
announced that it will host an Investor & Analyst Update Call and live webcast
on Thursday, July 11, 2013, at 2:00 p.m. Eastern Time/12:00 p.m. Mountain
Time. The call will be hosted by Harold Wolcott, President and CEO, and
William Barth, CFO.

Individuals interested in participating in the conference call may do so by
visiting the Investor Relations section of the Company's website at
www.BSDMedical.com or by dialing 877-941-8609 from the United States, or
480-629-9692 from outside the United States, and entering conference ID
4626960. We request that you RSVP to the conference call by emailing
tross@finprofiles.com before 4:00 p.m. Eastern Time on Tuesday, July 9, 2013.

A telephone replay will be available through July 18, 2013, by dialing
800-406-7325 from the United States, or 303-590-3030 from outside the United
States, and entering conference ID 4626960. A webcast replay will be available
for 90 days.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia), while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.

Contact:

BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
investor@bsdmc.com
or
Financial Profiles
Tricia Ross, 916-939-7285
tross@finprofiles.com